SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update after the market close on Tuesday, March 23, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:


Tuesday, March 23rd @ 5:00 p.m. EDT / 2:00 p.m. PDT

Domestic: 844-358-9116

International: 209-905-5951

Conference ID: 3291668

Webcast:


http://investors.atyrpharma.com/events-and-webcasts

Abo


ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit

.

Contact:


Ashlee Dunston

Director, Investor Relations and Corporate Communications


[email protected]